17617-23-1

Basic information

• Product Name: FLURAZEPAM
• Synonyms: 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(2-(diethylamino)ethyl)-5-(o-fluorophenyl)-;2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-;2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-;2h-1,4-benzodiazepin-2-one,1,3-dihydro-7-chloro-1-(2-(diethylamino)ethyl)-5-(;2h-1,4-benzodiazepin-2-one,1,3-dihydro-7-chloro-1-(2-(diethylamino)ethyl)-5-(o;2h-1,4-benzodiazepin-2-one,7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophe;2h-1,4-benzodiazepin-2-one,7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluoropheny;3-dihydro-l)-
• CAS NO: 17617-23-1
• Molecular Formula: C₂₁H₂₃ClFN₃O
• Molecular Weight: 387.88
• EINECS: 241-591-7
• Mol File: 17617-23-1.mol
• Article Data: 1

Chemical Properties

• Melting Point: 77-82°
• Boiling Point: 551.4°Cat760mmHg
• Flash Point: 9℃
• Appearance: light yellow/solid
• Density: 1.2089 (estimate)
• Vapor Pressure: 3.34E-12mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: 2-8°C
• Solubility: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: <6 mg/
• PKA: pKa 1.90±0.05(H2O) (Uncertain);8.16±0.05 (Uncertain)
• CAS DataBase Reference: FLURAZEPAM(CAS DataBase Reference)
• NIST Chemistry Reference: FLURAZEPAM(17617-23-1)
• EPA Substance Registry System: FLURAZEPAM(17617-23-1)

Safety Data

• Hazard Codes: Xn,T,F
• Statements: 22-33-39/23/24/25-23/24/25-11
• Safety Statements: 1/2-22-36-45-36/37-16-7
• RIDADR: 3249
• WGK Germany: 3
• RTECS: DF0875000
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 17617-23-1(Hazardous Substances Data)

Usage

Description

Flurazepam (CRM) (Item No. 18160) is a certified reference material that is structurally categorized as a benzodiazepine. It acts as a partial agonist of the benzodiazepine site on GABAA receptors, potentiating the action of GABA with an EC50 value of 930 nM in neuronal chick spinal cord cultures. Through this signaling mechanism, flurazepam produces anxiolytic and sedative properties that have been implemented clinically in the treatment of insomnia but also carry a potential for misuse. This product is intended for forensic and research purposes.

Chemical Properties

Flurazepam is a pale yellow crystalline solid.

Uses

Anticonvulsant; relaxant (muscle); sedative-hypnotic Dalmane (Valeant.

Therapeutic Function

Hypnotic

Pharmacokinetics

Chlorazepate is yet another benzodiazepine that is rapidly metabolized (3-decarboxylation) to N-desmethyldiazepam and so shares similar clinical and pharmacokinetic properties to chlordiazepoxide and diazepam.

Side effects

The half-life of flurazepam is fairly long (~7 hours); consequently, it has the same potential as chlordiazepoxide and diazepam to produce cumulative clinical effects and side effects (e.g., excessive sedation) and residual pharmacological activity, even after discontinuation.

Safety Profile

Poison by intravenous routes. Moderately toxic by ingestion and subcutaneous routes. Experimental reproductive effects. Caution: May be habit forming. This is a controlled substance (depressant) listed in the US. Code of Federal Regulations, Title 21 Part 1308.14. When heated to decomposition it emits very toxic fumes of Cl-, Fand NOx. See also DIAZEPAM.

Potential Exposure

A Drug. Flurazepam is used as a seda tive in capsules or liquid form.

Metabolism

Flurazepam is administered orally as the dihydrochloride salt. It is rapidly 1N-dealkylated to give the 2′-fluoro derivative of N-desmethyldiazepam, and it subsequently follows the same metabolic pathways as chlordiazepoxide and diazepam.

Shipping

UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials.

Waste Disposal

It is inappropriate and possi bly dangerous to the environment to dispose of expired or waste drugs and pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quanti ties of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

InChI:InChI=1/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3

Downstream Products

• 784-38-3 2-amino-5-chloro-2'-fluorobenzophenone 
• 2886-65-9 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2(2H)-one 

Relevant articles and documents

Process for the preparation of 1,4-benzodiazepine derivatives

A 1,4-benzodiazepine derivative, or a pharmaceutically acceptable acid salt thereof, of the formula, SPC1 Wherein R1 is hydrogen, halogen, nitro or trifluoromethyl; R2 and R3 are independently hydrogen, halogen, lower alkyl or trifluoromethyl; R4 is lower alkyl, alkenyl, trihaloalkyl, alkoxyalkyl, alkenyloxyalkyl, alkoxyalkoxyalkyl, alkanoyloxyalkyl, cycloalkylalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl or a group of the formula EQU1 in which R6 and R7 are independently lower alkyl, and n is an integer of 1 to 4; and R5 is hydrogen or lower alkyl, is obtained by reacting a benzophenone derivative of the formula, SPC2 Wherein R1, R2, R3 and R4 are as defined above, with a 2-isocyanatoacetyl chloride derivative of the formula EQU2 wherein R5 is as defined above.